Alnylam Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly filing, with total revenues reaching $1.25 billion for the three months ended September 30, 2025, a 149% increase from $500.9 million in the same period last year. For the nine months ending September 30, 2025, revenues totaled $2.62 billion, up 58% from $1.66 billion in 2024. The company achieved net product revenues of $851.1 million in Q3 2025, a 103% increase compared to $420.1 million in Q3 2024, primarily driven by strong sales of its flagship product, AMVUTTRA, which saw a 214% increase in U.S. sales.
The substantial revenue growth was attributed to increased demand for AMVUTTRA, particularly among patients with hereditary transthyretin-mediated amyloidosis with cardiomyopathy. However, sales of ONPATTRO, another key product, declined as patients transitioned to AMVUTTRA. The company also recognized $351.7 million in collaboration revenues, a significant increase from $57.4 million in the prior year, largely due to a $300 million milestone payment from Roche related to the dosing of the first patient in a Phase 3 trial for zilebesiran.
Alnylam's operating expenses also rose, totaling $881 million in Q3 2025, a 52% increase from $577.8 million in Q3 2024. This rise was driven by higher costs associated with research and development, which amounted to $358.8 million, and selling, general, and administrative expenses, which reached $322.1 million. The company reported a net income of $251.1 million for the quarter, a significant turnaround from a net loss of $111.6 million in the same quarter last year.
In terms of strategic developments, Alnylam has expanded its product pipeline and collaborations. The company initiated a Phase 3 trial for zilebesiran and reported positive results from its ongoing clinical trials for other investigational therapies. As of September 30, 2025, Alnylam had six marketed products and over 20 clinical programs, indicating a robust pipeline for future growth. The company also entered into a $500 million revolving credit agreement to support its operational needs and future growth initiatives.
Looking ahead, Alnylam aims to achieve sustainable operating profitability by 2025, while continuing to invest in its research and development efforts. The company believes its current cash, cash equivalents, and marketable securities will be sufficient to meet its capital and operating needs for at least the next 12 months. However, it acknowledges the potential for additional funding requirements as it expands its commercial and clinical operations.
About ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. With five approved products, including ONPATTRO and AMVUTTRA, Alnylam targets rare diseases like hereditary transthyretin-mediated amyloidosis. The company aims to expand its pipeline with over 20 clinical programs, focusing on high unmet medical needs. Alnylam's strategic initiatives, including collaborations with Roche and Novartis, support its goal of becoming a top-tier biotech by 2025.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.